Literature DB >> 7695283

Influence of host cell type and V3 loop of the surface glycoprotein on susceptibility of human immunodeficiency virus type 1 to polyanion compounds.

P R Meylan1, R S Kornbluth, I Zbinden, D D Richman.   

Abstract

Dextran sulfate is a potent inhibitor of human immunodeficiency virus (HIV) binding and replication in lymphocytic cell lines. In this study, we demonstrate that the effect of dextran sulfate and heparin depends on the host cell type and on the V3 loop, the principal neutralizing determinant of HIV gp120. In particular, when dextran sulfate was tested on primary human macrophages infected with macrophage-tropic viruses, enhancement of infection was observed in 6 of 11 independent macrophage preparations and with 5 of 13 primary HIV isolates. Our in vitro observations might explain why enhanced HIV replication was observed in HIV-infected patients treated with dextran sulfate.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7695283      PMCID: PMC188307          DOI: 10.1128/AAC.38.12.2910

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  36 in total

1.  Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro.

Authors:  M Ito; M Baba; A Sato; R Pauwels; E De Clercq; S Shigeta
Journal:  Antiviral Res       Date:  1987-07       Impact factor: 5.970

2.  Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus.

Authors:  M Baba; R Snoeck; R Pauwels; E de Clercq
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191

3.  Oral dextran sulfate (UA001) in the treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex.

Authors:  D I Abrams; S Kuno; R Wong; K Jeffords; M Nash; J B Molaghan; R Gorter; R Ueno
Journal:  Ann Intern Med       Date:  1989-02-01       Impact factor: 25.391

4.  Dextran sulfate is poorly absorbed after oral administration.

Authors:  K J Lorentsen; C W Hendrix; J M Collins; D M Kornhauser; B G Petty; R W Klecker; C Flexner; R H Eckel; P S Lietman
Journal:  Ann Intern Med       Date:  1989-10-01       Impact factor: 25.391

5.  Dextran sulfate and heparin interact with CD4 molecules to inhibit the binding of coat protein (gp120) of HIV.

Authors:  S Lederman; R Gulick; L Chess
Journal:  J Immunol       Date:  1989-08-15       Impact factor: 5.422

6.  Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy.

Authors:  D D Richman; D Havlir; J Corbeil; D Looney; C Ignacio; S A Spector; J Sullivan; S Cheeseman; K Barringer; D Pauletti
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

7.  Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro.

Authors:  M Baba; R Pauwels; J Balzarini; J Arnout; J Desmyter; E De Clercq
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

8.  Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells.

Authors:  H Mitsuya; D J Looney; S Kuno; R Ueno; F Wong-Staal; S Broder
Journal:  Science       Date:  1988-04-29       Impact factor: 47.728

9.  Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry.

Authors:  A Takeda; C U Tuazon; F A Ennis
Journal:  Science       Date:  1988-10-28       Impact factor: 47.728

10.  Interferons and bacterial lipopolysaccharide protect macrophages from productive infection by human immunodeficiency virus in vitro.

Authors:  R S Kornbluth; P S Oh; J R Munis; P H Cleveland; D D Richman
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

View more
  13 in total

1.  Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities.

Authors:  S Rusconi; M Moonis; D P Merrill; P V Pallai; E A Neidhardt; S K Singh; K J Willis; M S Osburne; A T Profy; J C Jenson; M S Hirsch
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

2.  Mandelic acid condensation polymer: novel candidate microbicide for prevention of human immunodeficiency virus and herpes simplex virus entry.

Authors:  B C Herold; I Scordi-Bello; N Cheshenko; D Marcellino; M Dzuzelewski; F Francois; R Morin; V Mas Casullo; R A Anderson; C Chany; D P Waller; L J D Zaneveld; M E Klotman
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

3.  Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections.

Authors:  Shaun K Rodriguez; Abdoulaye Dieng Sarr; Adam MacNeil; Seema Thakore-Meloni; Aissatou Gueye-Ndiaye; Ibrahima Traoré; Mamadou C Dia; Souleymane Mboup; Phyllis J Kanki
Journal:  J Virol       Date:  2007-02-14       Impact factor: 5.103

4.  Design, synthesis, antiviral activity, and pre-formulation development of poly-L-arginine-fatty acyl derivatives of nucleoside reverse transcriptase inhibitors.

Authors:  Bhanu P Pemmaraju; Swapnil Malekar; Hitesh K Agarwal; Rakesh K Tiwari; Donghoon Oh; Gustavo F Doncel; David R Worthen; Keykavous Parang
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2015       Impact factor: 1.381

5.  RhoA-derived peptide dimers share mechanistic properties with other polyanionic inhibitors of respiratory syncytial virus (RSV), including disruption of viral attachment and dependence on RSV G.

Authors:  Philip J Budge; Yeqiang Li; Judy A Beeler; Barney S Graham
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

6.  Enhancement of HIV infection by cellulose sulfate.

Authors:  Wang Tao; Chris Richards; Dean Hamer
Journal:  AIDS Res Hum Retroviruses       Date:  2008-07       Impact factor: 2.205

7.  Whither or wither microbicides?

Authors:  Robert M Grant; Dean Hamer; Thomas Hope; Rowena Johnston; Joep Lange; Michael M Lederman; Judy Lieberman; Christopher J Miller; John P Moore; Donald E Mosier; Douglas D Richman; Robert T Schooley; Marty S Springer; Ronald S Veazey; Mark A Wainberg
Journal:  Science       Date:  2008-07-25       Impact factor: 47.728

8.  Enhancement of human immunodeficiency virus type 1 replication is not intrinsic to all polyanion-based microbicides.

Authors:  Secondo Sonza; Adam Johnson; David Tyssen; Tim Spelman; Gareth R Lewis; Jeremy R A Paull; Gilda Tachedjian
Journal:  Antimicrob Agents Chemother       Date:  2009-06-15       Impact factor: 5.191

9.  Contribution of proteoglycans to human immunodeficiency virus type 1 brain invasion.

Authors:  Michael D Bobardt; Patrick Salmon; Lianchun Wang; Jeffrey D Esko; Dana Gabuzda; Milan Fiala; Didier Trono; Bernadette Van der Schueren; Guido David; Philippe A Gallay
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

10.  Human defensins 5 and 6 enhance HIV-1 infectivity through promoting HIV attachment.

Authors:  Aprille Rapista; Jian Ding; Bernadette Benito; Yung-Tai Lo; Matthew B Neiditch; Wuyuan Lu; Theresa L Chang
Journal:  Retrovirology       Date:  2011-06-14       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.